September 25, 2023Open Access

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Key Points

Key points are not available for this paper at this time.

Abstract

SURPASS-CVOT will provide definitive evidence as to the CV safety and efficacy of tirzepatide as compared with dulaglutide, a GLP-1 receptor agonist with established CV benefit.

Read Full Paperexternally

问 AI

Bookmark

View Full Paper

Cite This Study

Nicholls et al. (Mon,) studied this question.

synapsesocial.com/papers/69a607599cf1ac82ad736679 https://doi.org/https://doi.org/10.1016/j.ahj.2023.09.007

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials2021 · 1,509 citations
2Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo2015 · 99 citations
3Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015 · 12,025 citations
4Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes2022 · 566 citations
5Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials2019 · 1,623 citations

问 AI

Bookmark

View Full Paper